NCT03583697 - A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

January 26, 2022

Study Completion Date

January 26, 2022

Conditions

Achondroplasia

Interventions

DRUG

BMN 111

Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol

DRUG

Placebo

Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol

Trial Locations (16)

2145

The Children's Hospital at Westmead, Westmead

3052

Murdoch Children's Research Institute, Parkville

19803

Alfred I. duPont Hospital for Children, Wilmington

30033

Emory University, Decatur

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

53226

Medical College of Wisconsin, Children's Hospital, Milwaukee

60611

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

77030

Baylor College of Medicine, Houston

90509

Harbor - UCLA Medical Center, Torrance

94609

Children's Hospital & Research Center Oakland, Oakland

37232-2578

Vanderbilt University Medical Center, Nashville

Unknown

Osaka University Hospital, Osaka

Saitama Children's Medical Center, Saitama

Tokushima University Hospital, Tokushima

SE1 9RT

Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital, London

S10 2TH

Sheffield Children's NHS Foundation Trust, Sheffield